积雪草总苷缓释微丸的研究
|
摘要
积雪草(Cent el la asiatica (L.) Urb.)为伞形科积雪草属植物积雪草的干燥全草,在许多国家和地区的传统医药领域里中的应用已有几千年历史,我国中医药对积雪草的内服和外用也已有两千多年的历史,广东民间现在仍常用之制备凉茶。目前临床上主要用于治疗烧伤、抑制瘢痕增生作用、抗抑郁作用等。积雪草抗胃溃疡作用已有报导,但国内目前尚无积雪草用于治疗胃溃疡的药物上市。
积雪草药材为《中国药典》2005版首次收录,在《中国药典》2010版中又新增积雪草总苷条目。本积雪草总苷缓释微丸以现代制药技术为主要手段,将积雪草药材的有效部位积雪草总苷研制成具有明确治疗胃溃疡作用的新药。本文主要开展了以下几方面的研究工作,取得了较满意的结果。
1.针对积雪草总苷这一目标成分,建立了TLC定性鉴别方法,UV和HPLC的定量分析方法,方法准确可靠,简便快速,为积雪草总苷缓释微丸的研究提供了有效的分析手段。在TLC色谱研究中,经过对比研究采用了氯仿-甲醇-水(13：7：2)展开系统,显色剂为10%硫酸乙醇溶液,经过实验研究证实更为有效。药材前处理经对比性实验研究选择甲醇为提取溶剂,提取方法为超声提取。利用高效液相色谱仪中二极管阵列检测器的波长扫描功能,选择205nm作为检测波长,与《中国药典》2010版积雪草总苷条目下高效液相色谱法中的检测波长一致。色谱条件为,色谱柱：KromasilC18柱(4.6×250mm,5μm)；流动相：乙腈：水溶液=26：74；流速：1ml／min；检测波长：205nm；柱温：25℃。
2.积雪草总苷提取精制工艺研究中,进行了以积雪草总苷含量、积雪草总苷提取率和干浸膏得率为监测指标,对提取、纯化工艺优化。单因素考察提取溶媒对积雪草总苷含量的影响。采用正交设计以乙醇浓度、溶剂用量、提取时间和提取次数这四个工艺参数为因素,优选出提取工艺为：取积雪草总苷药材,用8倍量50%乙醇煮沸回流提取3次。采用不同AB-8、D-101、HPD200、HPD100大孔树脂法优选纯化工艺,结果以AB-8大孔树脂法最好,除杂速度快,指标性成分转移率高,精制度达到328.81%。积雪草总苷在干浸膏中的含量为56.21%。积雪草提取液纯化工艺为：取积雪草0.0625g生药／mL的浓缩液,按生药与树脂比例为1：1上AB-8大孔吸附树脂柱,药液以1ml／min的流速上柱吸附,先用1BV 10%乙醇溶液以1ml／min的流速进行洗脱,再用2BV70%乙醇进行洗脱,洗脱流速为1ml／min,收集洗脱液,70℃以下旋转蒸发仪减压回收乙醇,直至浓缩至相对密度1.15g／ml(70℃),70℃真空干燥,干膏以粉碎机粉碎,备用。
3.对积雪草总苷的主要理化性质进行了测试。结果表明纯化水和稀盐酸均可作为积雪草总苷在体外溶出试验的溶媒。积雪草总苷提取物粉末的孔隙率相对较大,平均堆密度为0.652 g／ml。该药粉休止角大于40°,流动性不好。相对湿度在54%下药粉的吸水率较小,而在54%以上药粉吸湿性明显增加,较易吸湿。积雪草总苷对光、热、湿稳定。采用TLC法研究积雪草总苷提取物与部分拟采用辅料的相互作用,结果表明积雪草总苷与HPMC、EC、卡波姆934P、乳糖、硬脂酸未发生配伍变化。在人工胃液和人工肠液测试条件下,卡波姆(carbomer)均能在比其它成分更低的浓度下,提供药物的控制释放作用。因此,拟选用卡波姆934P为主要辅料。
4.在参考文献的基础上,通过考察各种影响成丸的因素,结合动物体内外胃黏膜表面实验和体外释放度测定结果,设计出了合适的制丸工艺,确定了最佳处方,由该处方在确定的工艺条件下制得的积雪草总苷素丸圆整度好,收率较高,具有缓释功能,达到了预期的目标。本积雪草总苷缓释微丸的处方确定如下：积雪草总苷50%、MCC25.5%、卡波姆934P13%、硬脂酸6.5、乙基纤维素5%、润湿剂为水。
积雪草总苷缓释微丸的制备工艺：将积雪草总苷提取物与辅料分别过80目筛,取13%(w)的卡波姆934P和硬脂酸6.5%(w)高速搅拌混匀,于60℃的恒温水浴中加热熔融后立即放入冰箱中冷却,2h后取出置于干燥器中放至室温,取出粉碎过80目筛；另取积雪草总苷提取物占总量50%的量和EC(5%)、MCC(25.5%),使之混合后,以水为润湿剂,通过挤出滚圆法制备微丸。制备好的微丸首先置于40℃干燥2h后再置于80℃热处理2h即得。筛分,得20-40目的目标微丸。
5.应用多功能制粒包衣机对挤出滚圆法制备的素丸进行缓释包衣。包衣液主要采用Killcoat SR30D。分别考察了处方因素和工艺因素,并采用中心复合设计-效应面优化法对包衣处方进行了条件优化。确定积雪草总苷缓释微丸的最终包衣工艺为：聚合物中Kollicoat SR30D比例为43.86%,包衣增重为20%。处方为：KollicoatSR30D43.86%、丙二醇2%、乳糖0.5%、水46.14%、二氧化钛0.5%、滑石粉2%、水5%。包衣条件参数：进风温度为60度；喷雾压力为0.08Mpm保护气压力为0.08Mpa；恒流泵流速调节为0.5-0.8ml／min；包衣增重10%；包衣后40℃下熟化12h
6.通过药效学研究证实,积雪草总苷在一定程度上可以清除氧自由基、提高机体抗氧化能力,刺激胃粘膜肉芽组织生长,促进炎症修复和溃疡愈合,对于胃溃疡具有一定的预防及治疗作用。实验结果显示,积雪草总苷高、中剂量组和雷贝拉唑钠组大鼠乙酸致慢性胃溃疡溃疡指数极显著低于模型组(P<0.05),积雪草总苷高、中剂量组显著低于猴头菌组(P<0.05),与雷贝拉唑钠组无显著性差异(P>0.05)。积雪草总苷高、中剂量均能显著降低大鼠溃疡指数,并呈一定的量效关系,说明积雪草总苷对于大鼠慢性乙酸型溃疡同样具有显著的修复作用。对乙酸法致胃溃疡模型胃组织SOD活性和MDA含量的影响方面,积雪草总苷高、中剂量组强于雷贝拉唑钠组。积雪草总苷高剂量组病理组织学主要表现：炎症细胞浸润以黏膜层为主,可见黏膜缺损区及其下炎性肉芽组织,可见少量纤维瘢痕组织增生修复。
Centella asiatica (Centella asiatica (L.) Urb.) is the whole dry plant of the Umbelliferae Centella asiatica-Centella asiatica, and was used as a traditional medicine for thousands of years in many countries and regions, in Chinese medicine it also has been used for oral and external for 2000 years,it is still used as one of the main raw material of Herbal tea in Guangdong too. Currently, Centella asiatica are used in clinical to treat burns, inhibite scar proliferation and antidepressant. Although it was reported that Centella asiatica could be used to cure gastric ulcer, there were no Centella asiatica for the treatment of gastric ulcer drug on domestic market yet.
Centella asiatica were included in Chinese Pharmacopoeia 2005 edition for the first time, and its active ingredients Asiaticosides added in the Chinese Pharmacopoeia 2010 edition as a new item.In this thesis use modern pharmaceutical technology to develop the effective parts of Centella asiatica herbs Asiaticosides to a clear treatment of gastric ulcer drug, and the the purpose of this thesis is to explore the best preparation process, quality standards and preliminary observe its anti-ulcer effects of Asiaticosides sustained-release pellets.
1. TLC qualitative distinction, UV and HPLC quantitative analysis methods were established for the target constituents measurement of Asiaticosides, those methods mentioned above are accurate and reliable, simple and rapid, and provides an effective analytical method of the studying Asiaticosides sustained-release pellets. In the TLC chromatograph research, after a comparative study, chloroform-methanol-water (13:7:2) were selected as developing systems,10% acid solution as developer sulfuric, and experiments proved its effective. A compared experiment founded that ultrasound with extraction solvent methyl alcohol is a best extraction method. High performance liquid chromatography with diode array detector and wavelength scanning function, and 205nm were used as detection wave length, which consistent with the highly effective liquid phase chromatography's examination wave length in Asiaticosides item in "Chinese Pharmacopoeia" 2010 Edition. The chromatograph conditions are:chromatographic column: KromasilC18 column (4.6×250mm,5μm); Flowing:Methyl cyanide:Peroxide solution= 26:74; Speed of flow:1ml/min; Examination wave length:205nm; The column is warm: 25℃.
2.In the refining research of Asiaticosides, the content of Asiaticosides extraction rate and yield of dry extract were used as monitoring indicators, to optimize the extraction and purification process. And observed the single factor effect of extraction solvent on Asiaticosides content. Orthogonal design was used to optimized the four factors related to extraction process:ethanol concentration, solvent volume, extraction time and number of process.The optimized extraction process are:Asiaticosides herbs were extract 3 times with eight times the volume of 50% ethanol boils backset. AB-8 macroporous resin was selected in purification process from AB-8, D-101, HPD200, HPD100, for its maximum cleaning speed, the highest transfer rate of the index components. The rate of extracting and the content of Asiaticosides in the dry extract is 328.81%,56.21%. respectively.Centella asiatica extract purification process described as follows:the concentrated solution (the grass of Centella asiatica 0.0625g in every 1mL solution), according to the ratio of raw herb and resin 1:1, was added in AB-8 macroporous resin column at first, 1ml/min,10% ethanol solution eluted, then lml/min,2BV 70% ethanol elution, the eluent was collected in the following rotary evaporator vacuum for the recovery of ethanol at 70℃, at last, when the relative density of the eluent reached 1.15g/ml (70℃), the eluent was dried in Vacuum drier at the degrade of 70℃, and the dry paste was smashed and reserved.
3.The main physical and chemical propertie of the Asiaticosides's were tested. The results indicated that the purified water and dilute hydrochloric acid can be used as Asiaticosides solvent in the dissolution test. The porosity of Asiaticosides extract powder is relatively large, the average bulk density was 0.652 g/ml. The angle of repose of Asiaticosides extract powder is more than 40°, the fluidity is not good, and the relative humidity is small in 54% medicinal powder's water-absorptivity, but in 54% above the medicinal powder water absorbability increases obviously. Asiaticosides shows stability in light, heat, moisture conditions. The interaction between Asiaticosides extract and some accessories to be adopted,by TLC, and the results show that no changes occurred in Asiaticosides combined with HPMC, EC, carbomer 934P, lactose, stearic acid. In artificial gastric juice and intestinal fluid, Kabo (carbomer) could provide the controlled release of drug effect, in a lower density than other ingredient, as a result, Carbomer 934P was selected as the main accessories.
4. Based on the references studying, both the appropriate suitable pill preparative technology and the best prescription were designed, by inspecting each factors related to pill formation craft, combined with the results of the stomach mucous membrane surface experiment in vivo and release test in vitro. The prescription determination of the micro pill is as follows:Asiaticosides(50% of the total amount), MCC, (25.5%, of the total amount), carbomer 934P(13% of the total amount), stearic acid (6.5% of the total amount), ethyl cellulose(5% of the total amount),, wetting agent are the water。The cat's foot total glucoside 50%, MCC25.5%, Kabo 934P13%, stearic acid 6.5, ethyl cellulose 5%,.This Asiaticoside extended-release pellets show better pill roundness, higher yield,and the extended-release satisfied the anticipated demand, under selected pill preparative technology total glucoside releases slowly The preparation craft of Asiaticosides sustained-release pellets are as follows:Asiaticosides extracts and accessories were filtrated by 80 mesh filter, and mixed with 13%(w) Carbopol 934P and stearic acid 6.5%(w) at a high-speed stiring, refrigeraeted 2h immediately after melted in a constant temperature water bath at 60℃, then were put in a dryer to room temperature, crushed and the grinding through 80 mesh sieve at last; More Asiaticosides mixed with MCC, (25.5%, of the total amount), carbomer 934P(13% of the total amount), stearic acid (6.5% of the total amount), ethyl cellulose(5% of the total amount), and water(the wetting agent),were prepared the micro pellets through the Extrusion spheronization system, the prepared micro pellets first put in a desiccator drying 2h,at the 40℃, then heated 80℃for 2h, the purpose micro pellets were Picked out form a 20～40 mesh sieve.
5. The purpose micro pellets were coated with the Release coating fluid:Killcoat SR30D, by using the multifunctional Coating Machine Granulator. Prescription and process factors were investigated, and the Prescription of Release coating fluid were optimizated with the method of central composite design-response surface. The final coating process of Asiaticosides sustained-release pellets are:the polymer contains 43.86% Kollicoat SR30D, and the coating weight add by 20%.. Prescription are:43.86% Kollicoat SR30D, 2% propylene glycol,0.5% lactose,46.14%water,0.5% titanium dioxide,2% talc,5% water. Parameters of:the coating conditions:60℃inlet air temperature,0.08Mpa spray pressure,0.08Mpa protective air pressure,0.5-0.8ml/min constant pump flow rate,10% added coating weight, and the coating curing for curing 12h at the temperature of 40℃.
6. Pharmacodynamic studies Confirmed that:To some extent Asiaticosides could scavenge oxygen free radicals, improve antioxidant capacity, stimulate the growth of granulation tissue mucosa, and promote inflammation damages and ulcer, all of these prove that the anti-gastric ulcer effects of Asiaticosides.The Animal experiments showed that compared with modle group, the ulcer indexies of rabeprazole sodium acetic acid and the asiaticosides high and middle dose group were significantly lower (P<0.05), the ulcer indexies of asiaticosides high and middle groups were significantly lower than Hericium group (P<0.05) and was not significant different from rabeprazole group(P> 0.05), all of these result reveals Asiaticosides show the anti-gastric ulcer effects in a dose-dependent manner, and could be used to treat the experimental ulcer in rats induced by acetic acid. SOD activity and MDA content of asiaticosides high and middle dose was stronger than rabeprazole sodium in Gastric tissue from Acetic acid induced gastric ulcer animals. Asiaticosides high dose histological examination showed that the inflammatory cell infiltration mainly infiltrated in mucous layer, a small amount of fibrous scar tissue and inflammatory granulation tissue around the mucosal were in visible.
积雪草药材为《中国药典》2005版首次收录,在《中国药典》2010版中又新增积雪草总苷条目。本积雪草总苷缓释微丸以现代制药技术为主要手段,将积雪草药材的有效部位积雪草总苷研制成具有明确治疗胃溃疡作用的新药。本文主要开展了以下几方面的研究工作,取得了较满意的结果。
1.针对积雪草总苷这一目标成分,建立了TLC定性鉴别方法,UV和HPLC的定量分析方法,方法准确可靠,简便快速,为积雪草总苷缓释微丸的研究提供了有效的分析手段。在TLC色谱研究中,经过对比研究采用了氯仿-甲醇-水(13：7：2)展开系统,显色剂为10%硫酸乙醇溶液,经过实验研究证实更为有效。药材前处理经对比性实验研究选择甲醇为提取溶剂,提取方法为超声提取。利用高效液相色谱仪中二极管阵列检测器的波长扫描功能,选择205nm作为检测波长,与《中国药典》2010版积雪草总苷条目下高效液相色谱法中的检测波长一致。色谱条件为,色谱柱：KromasilC18柱(4.6×250mm,5μm)；流动相：乙腈：水溶液=26：74；流速：1ml／min；检测波长：205nm；柱温：25℃。
2.积雪草总苷提取精制工艺研究中,进行了以积雪草总苷含量、积雪草总苷提取率和干浸膏得率为监测指标,对提取、纯化工艺优化。单因素考察提取溶媒对积雪草总苷含量的影响。采用正交设计以乙醇浓度、溶剂用量、提取时间和提取次数这四个工艺参数为因素,优选出提取工艺为：取积雪草总苷药材,用8倍量50%乙醇煮沸回流提取3次。采用不同AB-8、D-101、HPD200、HPD100大孔树脂法优选纯化工艺,结果以AB-8大孔树脂法最好,除杂速度快,指标性成分转移率高,精制度达到328.81%。积雪草总苷在干浸膏中的含量为56.21%。积雪草提取液纯化工艺为：取积雪草0.0625g生药／mL的浓缩液,按生药与树脂比例为1：1上AB-8大孔吸附树脂柱,药液以1ml／min的流速上柱吸附,先用1BV 10%乙醇溶液以1ml／min的流速进行洗脱,再用2BV70%乙醇进行洗脱,洗脱流速为1ml／min,收集洗脱液,70℃以下旋转蒸发仪减压回收乙醇,直至浓缩至相对密度1.15g／ml(70℃),70℃真空干燥,干膏以粉碎机粉碎,备用。
3.对积雪草总苷的主要理化性质进行了测试。结果表明纯化水和稀盐酸均可作为积雪草总苷在体外溶出试验的溶媒。积雪草总苷提取物粉末的孔隙率相对较大,平均堆密度为0.652 g／ml。该药粉休止角大于40°,流动性不好。相对湿度在54%下药粉的吸水率较小,而在54%以上药粉吸湿性明显增加,较易吸湿。积雪草总苷对光、热、湿稳定。采用TLC法研究积雪草总苷提取物与部分拟采用辅料的相互作用,结果表明积雪草总苷与HPMC、EC、卡波姆934P、乳糖、硬脂酸未发生配伍变化。在人工胃液和人工肠液测试条件下,卡波姆(carbomer)均能在比其它成分更低的浓度下,提供药物的控制释放作用。因此,拟选用卡波姆934P为主要辅料。
4.在参考文献的基础上,通过考察各种影响成丸的因素,结合动物体内外胃黏膜表面实验和体外释放度测定结果,设计出了合适的制丸工艺,确定了最佳处方,由该处方在确定的工艺条件下制得的积雪草总苷素丸圆整度好,收率较高,具有缓释功能,达到了预期的目标。本积雪草总苷缓释微丸的处方确定如下：积雪草总苷50%、MCC25.5%、卡波姆934P13%、硬脂酸6.5、乙基纤维素5%、润湿剂为水。
积雪草总苷缓释微丸的制备工艺：将积雪草总苷提取物与辅料分别过80目筛,取13%(w)的卡波姆934P和硬脂酸6.5%(w)高速搅拌混匀,于60℃的恒温水浴中加热熔融后立即放入冰箱中冷却,2h后取出置于干燥器中放至室温,取出粉碎过80目筛；另取积雪草总苷提取物占总量50%的量和EC(5%)、MCC(25.5%),使之混合后,以水为润湿剂,通过挤出滚圆法制备微丸。制备好的微丸首先置于40℃干燥2h后再置于80℃热处理2h即得。筛分,得20-40目的目标微丸。
5.应用多功能制粒包衣机对挤出滚圆法制备的素丸进行缓释包衣。包衣液主要采用Killcoat SR30D。分别考察了处方因素和工艺因素,并采用中心复合设计-效应面优化法对包衣处方进行了条件优化。确定积雪草总苷缓释微丸的最终包衣工艺为：聚合物中Kollicoat SR30D比例为43.86%,包衣增重为20%。处方为：KollicoatSR30D43.86%、丙二醇2%、乳糖0.5%、水46.14%、二氧化钛0.5%、滑石粉2%、水5%。包衣条件参数：进风温度为60度；喷雾压力为0.08Mpm保护气压力为0.08Mpa；恒流泵流速调节为0.5-0.8ml／min；包衣增重10%；包衣后40℃下熟化12h
6.通过药效学研究证实,积雪草总苷在一定程度上可以清除氧自由基、提高机体抗氧化能力,刺激胃粘膜肉芽组织生长,促进炎症修复和溃疡愈合,对于胃溃疡具有一定的预防及治疗作用。实验结果显示,积雪草总苷高、中剂量组和雷贝拉唑钠组大鼠乙酸致慢性胃溃疡溃疡指数极显著低于模型组(P<0.05),积雪草总苷高、中剂量组显著低于猴头菌组(P<0.05),与雷贝拉唑钠组无显著性差异(P>0.05)。积雪草总苷高、中剂量均能显著降低大鼠溃疡指数,并呈一定的量效关系,说明积雪草总苷对于大鼠慢性乙酸型溃疡同样具有显著的修复作用。对乙酸法致胃溃疡模型胃组织SOD活性和MDA含量的影响方面,积雪草总苷高、中剂量组强于雷贝拉唑钠组。积雪草总苷高剂量组病理组织学主要表现：炎症细胞浸润以黏膜层为主,可见黏膜缺损区及其下炎性肉芽组织,可见少量纤维瘢痕组织增生修复。
Centella asiatica (Centella asiatica (L.) Urb.) is the whole dry plant of the Umbelliferae Centella asiatica-Centella asiatica, and was used as a traditional medicine for thousands of years in many countries and regions, in Chinese medicine it also has been used for oral and external for 2000 years,it is still used as one of the main raw material of Herbal tea in Guangdong too. Currently, Centella asiatica are used in clinical to treat burns, inhibite scar proliferation and antidepressant. Although it was reported that Centella asiatica could be used to cure gastric ulcer, there were no Centella asiatica for the treatment of gastric ulcer drug on domestic market yet.
Centella asiatica were included in Chinese Pharmacopoeia 2005 edition for the first time, and its active ingredients Asiaticosides added in the Chinese Pharmacopoeia 2010 edition as a new item.In this thesis use modern pharmaceutical technology to develop the effective parts of Centella asiatica herbs Asiaticosides to a clear treatment of gastric ulcer drug, and the the purpose of this thesis is to explore the best preparation process, quality standards and preliminary observe its anti-ulcer effects of Asiaticosides sustained-release pellets.
1. TLC qualitative distinction, UV and HPLC quantitative analysis methods were established for the target constituents measurement of Asiaticosides, those methods mentioned above are accurate and reliable, simple and rapid, and provides an effective analytical method of the studying Asiaticosides sustained-release pellets. In the TLC chromatograph research, after a comparative study, chloroform-methanol-water (13:7:2) were selected as developing systems,10% acid solution as developer sulfuric, and experiments proved its effective. A compared experiment founded that ultrasound with extraction solvent methyl alcohol is a best extraction method. High performance liquid chromatography with diode array detector and wavelength scanning function, and 205nm were used as detection wave length, which consistent with the highly effective liquid phase chromatography's examination wave length in Asiaticosides item in "Chinese Pharmacopoeia" 2010 Edition. The chromatograph conditions are:chromatographic column: KromasilC18 column (4.6×250mm,5μm); Flowing:Methyl cyanide:Peroxide solution= 26:74; Speed of flow:1ml/min; Examination wave length:205nm; The column is warm: 25℃.
2.In the refining research of Asiaticosides, the content of Asiaticosides extraction rate and yield of dry extract were used as monitoring indicators, to optimize the extraction and purification process. And observed the single factor effect of extraction solvent on Asiaticosides content. Orthogonal design was used to optimized the four factors related to extraction process:ethanol concentration, solvent volume, extraction time and number of process.The optimized extraction process are:Asiaticosides herbs were extract 3 times with eight times the volume of 50% ethanol boils backset. AB-8 macroporous resin was selected in purification process from AB-8, D-101, HPD200, HPD100, for its maximum cleaning speed, the highest transfer rate of the index components. The rate of extracting and the content of Asiaticosides in the dry extract is 328.81%,56.21%. respectively.Centella asiatica extract purification process described as follows:the concentrated solution (the grass of Centella asiatica 0.0625g in every 1mL solution), according to the ratio of raw herb and resin 1:1, was added in AB-8 macroporous resin column at first, 1ml/min,10% ethanol solution eluted, then lml/min,2BV 70% ethanol elution, the eluent was collected in the following rotary evaporator vacuum for the recovery of ethanol at 70℃, at last, when the relative density of the eluent reached 1.15g/ml (70℃), the eluent was dried in Vacuum drier at the degrade of 70℃, and the dry paste was smashed and reserved.
3.The main physical and chemical propertie of the Asiaticosides's were tested. The results indicated that the purified water and dilute hydrochloric acid can be used as Asiaticosides solvent in the dissolution test. The porosity of Asiaticosides extract powder is relatively large, the average bulk density was 0.652 g/ml. The angle of repose of Asiaticosides extract powder is more than 40°, the fluidity is not good, and the relative humidity is small in 54% medicinal powder's water-absorptivity, but in 54% above the medicinal powder water absorbability increases obviously. Asiaticosides shows stability in light, heat, moisture conditions. The interaction between Asiaticosides extract and some accessories to be adopted,by TLC, and the results show that no changes occurred in Asiaticosides combined with HPMC, EC, carbomer 934P, lactose, stearic acid. In artificial gastric juice and intestinal fluid, Kabo (carbomer) could provide the controlled release of drug effect, in a lower density than other ingredient, as a result, Carbomer 934P was selected as the main accessories.
4. Based on the references studying, both the appropriate suitable pill preparative technology and the best prescription were designed, by inspecting each factors related to pill formation craft, combined with the results of the stomach mucous membrane surface experiment in vivo and release test in vitro. The prescription determination of the micro pill is as follows:Asiaticosides(50% of the total amount), MCC, (25.5%, of the total amount), carbomer 934P(13% of the total amount), stearic acid (6.5% of the total amount), ethyl cellulose(5% of the total amount),, wetting agent are the water。The cat's foot total glucoside 50%, MCC25.5%, Kabo 934P13%, stearic acid 6.5, ethyl cellulose 5%,.This Asiaticoside extended-release pellets show better pill roundness, higher yield,and the extended-release satisfied the anticipated demand, under selected pill preparative technology total glucoside releases slowly The preparation craft of Asiaticosides sustained-release pellets are as follows:Asiaticosides extracts and accessories were filtrated by 80 mesh filter, and mixed with 13%(w) Carbopol 934P and stearic acid 6.5%(w) at a high-speed stiring, refrigeraeted 2h immediately after melted in a constant temperature water bath at 60℃, then were put in a dryer to room temperature, crushed and the grinding through 80 mesh sieve at last; More Asiaticosides mixed with MCC, (25.5%, of the total amount), carbomer 934P(13% of the total amount), stearic acid (6.5% of the total amount), ethyl cellulose(5% of the total amount), and water(the wetting agent),were prepared the micro pellets through the Extrusion spheronization system, the prepared micro pellets first put in a desiccator drying 2h,at the 40℃, then heated 80℃for 2h, the purpose micro pellets were Picked out form a 20～40 mesh sieve.
5. The purpose micro pellets were coated with the Release coating fluid:Killcoat SR30D, by using the multifunctional Coating Machine Granulator. Prescription and process factors were investigated, and the Prescription of Release coating fluid were optimizated with the method of central composite design-response surface. The final coating process of Asiaticosides sustained-release pellets are:the polymer contains 43.86% Kollicoat SR30D, and the coating weight add by 20%.. Prescription are:43.86% Kollicoat SR30D, 2% propylene glycol,0.5% lactose,46.14%water,0.5% titanium dioxide,2% talc,5% water. Parameters of:the coating conditions:60℃inlet air temperature,0.08Mpa spray pressure,0.08Mpa protective air pressure,0.5-0.8ml/min constant pump flow rate,10% added coating weight, and the coating curing for curing 12h at the temperature of 40℃.
6. Pharmacodynamic studies Confirmed that:To some extent Asiaticosides could scavenge oxygen free radicals, improve antioxidant capacity, stimulate the growth of granulation tissue mucosa, and promote inflammation damages and ulcer, all of these prove that the anti-gastric ulcer effects of Asiaticosides.The Animal experiments showed that compared with modle group, the ulcer indexies of rabeprazole sodium acetic acid and the asiaticosides high and middle dose group were significantly lower (P<0.05), the ulcer indexies of asiaticosides high and middle groups were significantly lower than Hericium group (P<0.05) and was not significant different from rabeprazole group(P> 0.05), all of these result reveals Asiaticosides show the anti-gastric ulcer effects in a dose-dependent manner, and could be used to treat the experimental ulcer in rats induced by acetic acid. SOD activity and MDA content of asiaticosides high and middle dose was stronger than rabeprazole sodium in Gastric tissue from Acetic acid induced gastric ulcer animals. Asiaticosides high dose histological examination showed that the inflammatory cell infiltration mainly infiltrated in mucous layer, a small amount of fibrous scar tissue and inflammatory granulation tissue around the mucosal were in visible.
引文
[1]章臣桂,李静.中药制剂的发展历程与体会[J].中草药,2000；31(增刊)：5-7
[2]张景勃,张志荣.中药靶向给药系统的研究进展[J].中草药,2000；31(增刊)：23-24
[3]罗国安.中成药研究概况[J].中成药,2001；
[4]祁少海,谢举临,利天增等.积雪草苷对烧伤增生性瘢痕作用的实验研究[J].中华烧伤杂志,2000,16(1)：53-56.
[5]范哲,温泉.荆花胃康胶丸治疗胃溃疡疗效观察[J].中国全科医学.2009,12(5)：429-430.
[6]林海呜,许琼明,等。猴头菌抗胃溃疡作用的研究.中草药.2008,39(12)：1681-1683.
[7]江西第一人民医院消化组：新药学杂志,1979,20(3).
[8]邓晓鹏,门九章.中医药治疗复发性口腔溃疡临床研究进展[J].山西中医学院.2007年第8卷第2期.
[10]潘姝.积雪草苷对增生性瘢痕成纤维细胞TGF-p/Smads信号通路的影响[D].中山大学博士学位论文.
[11]周橘.积雪草总苷抗肿瘤作用及机制研究[D].苏州大学硕士学位论文.
[12]陈瑶.中药积雪草的品质评价和抗抑郁研究[D].第二军医大学博士学位论文.20030401.
[13]王磊等.积雪草甙对人成纤维细胞增殖的影响[J].齐齐哈尔医学院院报.2007年第28卷第19期.
[14]张兆辉.由消化性溃疡相关文献探讨中医治疗与处方用药规律[D].2006年5月.
[15]郭伦锋,郭庆东,王四旺.胃溃疡治疗药物的研究进展[J].亚太传统医药.2008,4(8)：78-80.
[16]李林,潘志恒,王竹立等.党参等中药对胃粘膜的快速保护作用[J].中国医师杂志.2001,3(2)：112-114.
[17]高明哲,袁晓艳,肖红斌.制备型高效液相色谱法从积雪草提取物中分离纯化积雪草甙和羟基积雪草甙对照品[J].色谱,2008,26(3)：362-365.
[18]陈怡,高文远,于泉林,等.田口试验设计法优选积雪草提取工艺[J].中国中药杂志,2007,32(16)：1714-1716.
[19]邹杰明,周艳林,吴敏菊HPLC-ELSD法测定三金片和三金胶囊中积雪草苷和羟基积雪草苷的含量[J].药物分析杂志,2005,25(10)：5-6.
[20]向前,杜书良,唐强,吴向东HPLC-ELSD法测定积雪草中积雪草苷的含量[J].成都中医药大学学 报,2007,30(1)：54-57.
[21]于泉林,高文远,陈海霞,段宏泉HPLC-ELSD测定积雪草提取物中积雪草苷的含量[J].中国中药杂志,2007,32(6)：503-505.
[22]陆兴毅,冯丽娟HPLC法测定积雪草总苷中羟基积雪草苷和积雪草苷的含量[J].中国药师,2008,11(1)：62-63.
[23]梁李广,马维.HPLC测定不同产地和不同时间的积雪草中的积雪草苷和羟基积雪草苷[J].华西药学杂志2009,24(2)：186-187.
[24]梁李广,刘华东.高效液相色谱法测定积雪草苷片中积雪草苷、羟基积雪草昔的含量[J].内蒙古中医药2008,2：35-36.
[25]高永艳,黎永洁.反相高效液相蒸发光散射检测法测定三金软胶囊中羟基积雪草苷含量[J].中国医药导报2008,5(29)：26-27
[26]郑小伟,王颖,汪婷婷.中医药治疗胃溃疡的实验研究概况[J].浙江中医杂志.2009,7(44)：535-537.
[27]王磊等.积雪草甙对人成纤维细胞增殖的影响[J].齐齐哈尔医学院院报,2007,28(19)：2311-2312.
[28]许宏俐.益气化淤煎剂抗大鼠胃溃疡作用及其机制探讨[J].中国中西结合消化杂志,1998,4(9)：21-22
[29]国家药典委员会.中华人民共和国药典2010版一部[S].北京：中国中医药出版社,2010.
[30]陈瑶,秦路平,郑汉臣,等.积雪草的资源分布于生药鉴别[J].中国中药杂志,2000,25(4)：199-202.
[31]余传隆,黄泰康,丁志遵,等.中药辞海[S].中国医药科技出版社,1993.12,2114.
[32]Srivastava Ritu, Shukla YN.Some chemical constituents from Centella asiatica. Idian Durgs,1996, 33(5):233.
[33]秦路平,丁如贤,张卫路,等.积雪草挥发油成分分析及其抗抑郁作用研究[J].第二军医大学学报,1998,19(2)：186.
[34]何明芳,孟正禾,沃连群.积雪草化学成分的研究[J].中国药科大学学报,2000,31(2)：91.
[35]张开莲,张炜.正交试验优化积雪草总苷提取工艺[J].中国药房,2008,19(21)：1618-1620.
[36]国家专利局.专利号：CN101463064A,CN101210040A.
[37]黄怀鹏,刘彩霞,高国领,等.大孔树脂纯化积雪草总苷的工艺研究[J].中药材,2008,31(7)：1072-1074.
[38]陈宝雯,纪宝安,张学智,等.积雪草提取物对胃黏膜的保护作用及其机制的探讨[J].中国消化 杂志,1999,19(4)：246-248.
[39]明志君,孙萌.积雪草苷抗炎作用的实验研究[J].中国中医药科技,2002,9(1)：62.
[40]Cheng CL, Koo MWL.Effect of Centella asiatica on ethanol-induced gastric mucosal lesionsin rats.Life Sci,2000,67(21):2647.
[41]乐锦茂,浦培黄,雪颖.复方积雪草浸膏对大白鼠慢性实验性胃溃疡及微循环的影响[J].江苏中医,1992,13(3)：42.
[42]Lung Cheng, Jin Sheng Guo, John Luk, Marcel Wing leung Koo.The healing effects of centrella extract and asiaticoside on acetic acid induced gastric unlcers in rats.Life Science,74(2004):2237-2249.
[43]陈宝雯,纪宝安,张学智,谢竹藩,贾博琦.积雪草提取物对胃粘膜的保护作用及其机制探讨[J].中华消化杂志,1999,19(4)：246.
[44]Chatterjec TK.Indian J.Exp Biol.1992,30(10):89-91.
[45]张涛,荣新洲,杨荣华,等.积雪草甙对增生性瘢痕中转化生长因子-βmRNA及基子金属蛋白酶类表达的影响[J].南方医科大学学报,2006,26(1)：67-70.
[46]潘姝,利天增,祁少海,等.积雪草对瘢痕成纤维细胞增殖与磷酸化Smad2和Smad7表达的影响[J].世界临床药物,2004,2(25)：99-102.
[47]张涛,利天增,祁少海,等.积雪草甙对烧伤创面愈合中细胞周期蛋白增殖细胞核抗原表达的影响[J].中华实验外科杂志,2005,1(22)：43-45.
[48]谢举临,利天增,祁少海,等.积雪草甙对体外培养的成纤维细胞的作用[J].中山医科大学学报,2001,22(1)：41-47.
[49]王瑞国,王锦菊,于祥彬,等.积雪草甙对成纤维细胞DNA合成与胶原蛋白合成的影响[J].福建中医学院学报,2001,11(2)：41.
[50]祁少海,谢举临,利天增,等.积雪草苷对烧伤增生性斑痕作用的实验研究,中华烧伤杂志,2000,16(1)：53-56.
[51]宋清华,狄春辉,崔鸣,等.积雪草昔对伤口愈合作用的基础研究[J].中国医药导刊,2000,2(5)：37-39.
[52]A.Shukla, A.M.Rasik, GK.Jain.R.Shankar, D.K.Kulshrestha, B.N.D hawan.In vitro wound healing activity of asiaticoside isolated from centella asiatica Journal of Ethnopharmcology,1999,65:1-11.
[53]张中启,袁莉,罗质璞.积雪草提取物抑制小鼠体外脑单胺氧化酶A的活性[J].军事医学科学院 院刊,2000,24(2)：158.
[54]秦路平,丁如贤,张卫路,等.积雪草挥发油成分分析及其抗抑郁作用研究[J].第二军医大学学报,1998,19(2)：186.
[55]朱濂溪,唐兆祺.单味积雪草治疗流行性腮腺炎35例[J].福建中医药,1990,2(4)：45.
[56]Ahmad Shahmuz, Rahman Atiq-ur, Fatima kaneez, et al. Amino acid analysis of Intellan, a herbalproduct used in enhancing brain function.Pak Pharm Sci,1994,7(2):17.
[57]Srivastava Ritu, Shula YN, Kumar Sushil.Chemistry and Pharmacology of Centella asiatica:a review. Med Aromat Plant Sci,1997,19(4):1049.
[58]Morganti P, Fionda A, Elia U et al.extraction and analysis of Cosmetic active ingredients from an anti-cellulitis transdermal delivery system by hign performance layer chromatography. Chromatogr Sci,1999,37(2):51.
[59]沈宗国.积雪草汤治疗病毒性肝炎伴溃疡病疗效观察[J].江西中医药,1995,36(6)：25.
[60]崔文华,刘光亮,李尧宾,等。积雪草治疗烧伤的止痛、防瘫痕疗效观察[J].中国临床康复,2002,6(6)：839.
[61]陈振南,林文清.大剂量积雪草在临床应用经验[J].海峡药学,1999,11(2)：88.
[52]刘纪萍,徐惠南.盐酸地尔硫卓控释微丸的研究[J].中国医药工业杂志,1996,27(9)：397-400.
[63]于杰,邹梅芬,郝秀华,等.中心复合设计法优化盐酸普罗帕酮缓释微丸包衣液处方[J].沈阳药科大学学报,2006,23(11)：686-709.
[64]施路,李三明,宋红光,等.不同包衣条件下银杏缓释微丸体外释放考察[J].沈阳药科大学学报,2005,22(3)：176-199.
[65]郭涛,郑春丽,宋洪涛,等.双氯芬酸钠脉冲控释微丸的研究[J].药学学报,2003,38(9)：707-710.
[66]张彦青,解军波,陈大为.灯盏花素骨架缓释微丸释药机制的研究[J].中草药,2004,35(5)：517-519.
[67]陆彬.中药新剂型新技术[M].化学工业出版社,2008：115.
[68]王巧玲,李爱婷,张亚军.挤出滚圆法制备溃结康微丸及其性质[J].陕西中医,2007,28(8)：1077-1078.
[69]王鲁敏,潘家祯,郭春林.中药浸膏微丸制备研究[J].中国药业,2005,14(8)：47-48.
[70]戚秋鹏.王中彦.刘天富.HPLC法测定万氏牛黄清心微丸中盐酸小檗碱和黄芩苷的含量[J].沈阳药科大学学报,2003,20(5)：352-355.
[71]洪燕龙,林晓,徐德生.流化床包衣法制备天麻效应组分缓释微丸的研究[J].中药材,2009,32(9)：1444-1447.
[72]沈熊,吴伟,徐惠南.口服结肠定位释药系统评价方法[J].中国临床药学杂志,2004,13(4)：250-253.
[73]吕志阳,狄留庆,李俊松,等.中药成型技术的研究进展[J].医药导报,2009,28(9)：1171-1173
[74]姚新生,胡柯.中药复方的现代化研究[J].化学进展1999,19(2).
[75]徐蓉娟主编.内科学.普通高等教育“十五”国家级规划教材[M].北京：中国中医药出版社.2003.1：181.
[76]何祥久,邱峰,姚新生.中药复方研究现状和思路[J].化学进展2001,13(6)：481-485.
[77]于成功,吴寒.质子泵抑制剂的临床应用与研究进展.中华消化内镜杂志.2007,24(2)：74-75.
[78]邹品文,赵春景.质子泵抑制剂研究进展和研究方向.药学专论[J].2008,2：23-24.
[79]杨辉.铝碳酸镁和奥美拉唑联合用药治疗活动期胃溃疡40例.中国新药与临床杂志.2006,25(10)：770-772.
[80]李健,唐芙爱.胃黏膜保护剂的临床应用评价[J].中国医院用药评价与分析2003,3(3：133-137).
[81]张林,刘文忠.铋剂在根除幽门螺杆菌治疗中的作用[M].幽门螺杆菌研究进展.上海科学技术文献出版社.
[82]吴超斌,钟菊英.硫糖铝致麻疹样皮疹[J].药物不良反应杂志.2002,3：202.
[83]林鸿,俞淑静,穆晓燕.思密达的药理与临床应用[J].中国航空工业医药,2001,1(3)：75.
[84]陈建民,任建林.胃黏膜保护剂临床应用进展[J].world chin J Digestol 2005 NoVember;13(21): 2620-2622.
[85]郭荣臻,张宗海.不同抗酸制剂合用抗生素治疗胃溃疡及消除Hp疗效观察[J].河北医学.2002,8(6)：527-528.
[86]黄小梅.奥美拉唑和阿莫西林、甲硝唑联合治疗胃溃疡合并出血疗效观察[J].中原医刊.2004.31(19)：43-44.
[87]傅继华,温涛,徐琛,等.芦荟多糖对动物实验性胃溃疡的影响[J].中草药.2006,37(6)：895-897.
[88]顾洪丽.柴胡舒肝散治疗慢性萎缩性胃炎的临床体会[J].中医药导报.2008,4(7)：67.
[89]马洁.膈下逐瘀汤化裁治疗慢性萎缩性胃炎68例[J].江苏中医药.2005,26(4)：18.
[90]王新美,李晓琴.丹栀逍遥散临床应用举隅[J].河北中医药学报.2004,19(4)：14-15.
[91]白雪峰,刘梅君等.黄芪建中汤治疗消化性溃疡机理应用分析[J].光明中医,2008,9(9)：1351.
[92]张仲一,高岚,等.当归建中汤抗胃溃疡的实验研究[C].中国·天津第四届国际中医学药学术交流会议：226-267
[93]薛蓉.疏肝健脾养胃汤治疗消化性溃疡36例[J].中西医结合和祖国医学,2008,12(10)：920-921.
[94]唐保东.胃黏膜保护剂在胃溃疡治疗中的研究进展[M].中国处方药2006.5.NO.50.
[2]张景勃,张志荣.中药靶向给药系统的研究进展[J].中草药,2000；31(增刊)：23-24
[3]罗国安.中成药研究概况[J].中成药,2001；
[4]祁少海,谢举临,利天增等.积雪草苷对烧伤增生性瘢痕作用的实验研究[J].中华烧伤杂志,2000,16(1)：53-56.
[5]范哲,温泉.荆花胃康胶丸治疗胃溃疡疗效观察[J].中国全科医学.2009,12(5)：429-430.
[6]林海呜,许琼明,等。猴头菌抗胃溃疡作用的研究.中草药.2008,39(12)：1681-1683.
[7]江西第一人民医院消化组：新药学杂志,1979,20(3).
[8]邓晓鹏,门九章.中医药治疗复发性口腔溃疡临床研究进展[J].山西中医学院.2007年第8卷第2期.
[10]潘姝.积雪草苷对增生性瘢痕成纤维细胞TGF-p/Smads信号通路的影响[D].中山大学博士学位论文.
[11]周橘.积雪草总苷抗肿瘤作用及机制研究[D].苏州大学硕士学位论文.
[12]陈瑶.中药积雪草的品质评价和抗抑郁研究[D].第二军医大学博士学位论文.20030401.
[13]王磊等.积雪草甙对人成纤维细胞增殖的影响[J].齐齐哈尔医学院院报.2007年第28卷第19期.
[14]张兆辉.由消化性溃疡相关文献探讨中医治疗与处方用药规律[D].2006年5月.
[15]郭伦锋,郭庆东,王四旺.胃溃疡治疗药物的研究进展[J].亚太传统医药.2008,4(8)：78-80.
[16]李林,潘志恒,王竹立等.党参等中药对胃粘膜的快速保护作用[J].中国医师杂志.2001,3(2)：112-114.
[17]高明哲,袁晓艳,肖红斌.制备型高效液相色谱法从积雪草提取物中分离纯化积雪草甙和羟基积雪草甙对照品[J].色谱,2008,26(3)：362-365.
[18]陈怡,高文远,于泉林,等.田口试验设计法优选积雪草提取工艺[J].中国中药杂志,2007,32(16)：1714-1716.
[19]邹杰明,周艳林,吴敏菊HPLC-ELSD法测定三金片和三金胶囊中积雪草苷和羟基积雪草苷的含量[J].药物分析杂志,2005,25(10)：5-6.
[20]向前,杜书良,唐强,吴向东HPLC-ELSD法测定积雪草中积雪草苷的含量[J].成都中医药大学学 报,2007,30(1)：54-57.
[21]于泉林,高文远,陈海霞,段宏泉HPLC-ELSD测定积雪草提取物中积雪草苷的含量[J].中国中药杂志,2007,32(6)：503-505.
[22]陆兴毅,冯丽娟HPLC法测定积雪草总苷中羟基积雪草苷和积雪草苷的含量[J].中国药师,2008,11(1)：62-63.
[23]梁李广,马维.HPLC测定不同产地和不同时间的积雪草中的积雪草苷和羟基积雪草苷[J].华西药学杂志2009,24(2)：186-187.
[24]梁李广,刘华东.高效液相色谱法测定积雪草苷片中积雪草苷、羟基积雪草昔的含量[J].内蒙古中医药2008,2：35-36.
[25]高永艳,黎永洁.反相高效液相蒸发光散射检测法测定三金软胶囊中羟基积雪草苷含量[J].中国医药导报2008,5(29)：26-27
[26]郑小伟,王颖,汪婷婷.中医药治疗胃溃疡的实验研究概况[J].浙江中医杂志.2009,7(44)：535-537.
[27]王磊等.积雪草甙对人成纤维细胞增殖的影响[J].齐齐哈尔医学院院报,2007,28(19)：2311-2312.
[28]许宏俐.益气化淤煎剂抗大鼠胃溃疡作用及其机制探讨[J].中国中西结合消化杂志,1998,4(9)：21-22
[29]国家药典委员会.中华人民共和国药典2010版一部[S].北京：中国中医药出版社,2010.
[30]陈瑶,秦路平,郑汉臣,等.积雪草的资源分布于生药鉴别[J].中国中药杂志,2000,25(4)：199-202.
[31]余传隆,黄泰康,丁志遵,等.中药辞海[S].中国医药科技出版社,1993.12,2114.
[32]Srivastava Ritu, Shukla YN.Some chemical constituents from Centella asiatica. Idian Durgs,1996, 33(5):233.
[33]秦路平,丁如贤,张卫路,等.积雪草挥发油成分分析及其抗抑郁作用研究[J].第二军医大学学报,1998,19(2)：186.
[34]何明芳,孟正禾,沃连群.积雪草化学成分的研究[J].中国药科大学学报,2000,31(2)：91.
[35]张开莲,张炜.正交试验优化积雪草总苷提取工艺[J].中国药房,2008,19(21)：1618-1620.
[36]国家专利局.专利号：CN101463064A,CN101210040A.
[37]黄怀鹏,刘彩霞,高国领,等.大孔树脂纯化积雪草总苷的工艺研究[J].中药材,2008,31(7)：1072-1074.
[38]陈宝雯,纪宝安,张学智,等.积雪草提取物对胃黏膜的保护作用及其机制的探讨[J].中国消化 杂志,1999,19(4)：246-248.
[39]明志君,孙萌.积雪草苷抗炎作用的实验研究[J].中国中医药科技,2002,9(1)：62.
[40]Cheng CL, Koo MWL.Effect of Centella asiatica on ethanol-induced gastric mucosal lesionsin rats.Life Sci,2000,67(21):2647.
[41]乐锦茂,浦培黄,雪颖.复方积雪草浸膏对大白鼠慢性实验性胃溃疡及微循环的影响[J].江苏中医,1992,13(3)：42.
[42]Lung Cheng, Jin Sheng Guo, John Luk, Marcel Wing leung Koo.The healing effects of centrella extract and asiaticoside on acetic acid induced gastric unlcers in rats.Life Science,74(2004):2237-2249.
[43]陈宝雯,纪宝安,张学智,谢竹藩,贾博琦.积雪草提取物对胃粘膜的保护作用及其机制探讨[J].中华消化杂志,1999,19(4)：246.
[44]Chatterjec TK.Indian J.Exp Biol.1992,30(10):89-91.
[45]张涛,荣新洲,杨荣华,等.积雪草甙对增生性瘢痕中转化生长因子-βmRNA及基子金属蛋白酶类表达的影响[J].南方医科大学学报,2006,26(1)：67-70.
[46]潘姝,利天增,祁少海,等.积雪草对瘢痕成纤维细胞增殖与磷酸化Smad2和Smad7表达的影响[J].世界临床药物,2004,2(25)：99-102.
[47]张涛,利天增,祁少海,等.积雪草甙对烧伤创面愈合中细胞周期蛋白增殖细胞核抗原表达的影响[J].中华实验外科杂志,2005,1(22)：43-45.
[48]谢举临,利天增,祁少海,等.积雪草甙对体外培养的成纤维细胞的作用[J].中山医科大学学报,2001,22(1)：41-47.
[49]王瑞国,王锦菊,于祥彬,等.积雪草甙对成纤维细胞DNA合成与胶原蛋白合成的影响[J].福建中医学院学报,2001,11(2)：41.
[50]祁少海,谢举临,利天增,等.积雪草苷对烧伤增生性斑痕作用的实验研究,中华烧伤杂志,2000,16(1)：53-56.
[51]宋清华,狄春辉,崔鸣,等.积雪草昔对伤口愈合作用的基础研究[J].中国医药导刊,2000,2(5)：37-39.
[52]A.Shukla, A.M.Rasik, GK.Jain.R.Shankar, D.K.Kulshrestha, B.N.D hawan.In vitro wound healing activity of asiaticoside isolated from centella asiatica Journal of Ethnopharmcology,1999,65:1-11.
[53]张中启,袁莉,罗质璞.积雪草提取物抑制小鼠体外脑单胺氧化酶A的活性[J].军事医学科学院 院刊,2000,24(2)：158.
[54]秦路平,丁如贤,张卫路,等.积雪草挥发油成分分析及其抗抑郁作用研究[J].第二军医大学学报,1998,19(2)：186.
[55]朱濂溪,唐兆祺.单味积雪草治疗流行性腮腺炎35例[J].福建中医药,1990,2(4)：45.
[56]Ahmad Shahmuz, Rahman Atiq-ur, Fatima kaneez, et al. Amino acid analysis of Intellan, a herbalproduct used in enhancing brain function.Pak Pharm Sci,1994,7(2):17.
[57]Srivastava Ritu, Shula YN, Kumar Sushil.Chemistry and Pharmacology of Centella asiatica:a review. Med Aromat Plant Sci,1997,19(4):1049.
[58]Morganti P, Fionda A, Elia U et al.extraction and analysis of Cosmetic active ingredients from an anti-cellulitis transdermal delivery system by hign performance layer chromatography. Chromatogr Sci,1999,37(2):51.
[59]沈宗国.积雪草汤治疗病毒性肝炎伴溃疡病疗效观察[J].江西中医药,1995,36(6)：25.
[60]崔文华,刘光亮,李尧宾,等。积雪草治疗烧伤的止痛、防瘫痕疗效观察[J].中国临床康复,2002,6(6)：839.
[61]陈振南,林文清.大剂量积雪草在临床应用经验[J].海峡药学,1999,11(2)：88.
[52]刘纪萍,徐惠南.盐酸地尔硫卓控释微丸的研究[J].中国医药工业杂志,1996,27(9)：397-400.
[63]于杰,邹梅芬,郝秀华,等.中心复合设计法优化盐酸普罗帕酮缓释微丸包衣液处方[J].沈阳药科大学学报,2006,23(11)：686-709.
[64]施路,李三明,宋红光,等.不同包衣条件下银杏缓释微丸体外释放考察[J].沈阳药科大学学报,2005,22(3)：176-199.
[65]郭涛,郑春丽,宋洪涛,等.双氯芬酸钠脉冲控释微丸的研究[J].药学学报,2003,38(9)：707-710.
[66]张彦青,解军波,陈大为.灯盏花素骨架缓释微丸释药机制的研究[J].中草药,2004,35(5)：517-519.
[67]陆彬.中药新剂型新技术[M].化学工业出版社,2008：115.
[68]王巧玲,李爱婷,张亚军.挤出滚圆法制备溃结康微丸及其性质[J].陕西中医,2007,28(8)：1077-1078.
[69]王鲁敏,潘家祯,郭春林.中药浸膏微丸制备研究[J].中国药业,2005,14(8)：47-48.
[70]戚秋鹏.王中彦.刘天富.HPLC法测定万氏牛黄清心微丸中盐酸小檗碱和黄芩苷的含量[J].沈阳药科大学学报,2003,20(5)：352-355.
[71]洪燕龙,林晓,徐德生.流化床包衣法制备天麻效应组分缓释微丸的研究[J].中药材,2009,32(9)：1444-1447.
[72]沈熊,吴伟,徐惠南.口服结肠定位释药系统评价方法[J].中国临床药学杂志,2004,13(4)：250-253.
[73]吕志阳,狄留庆,李俊松,等.中药成型技术的研究进展[J].医药导报,2009,28(9)：1171-1173
[74]姚新生,胡柯.中药复方的现代化研究[J].化学进展1999,19(2).
[75]徐蓉娟主编.内科学.普通高等教育“十五”国家级规划教材[M].北京：中国中医药出版社.2003.1：181.
[76]何祥久,邱峰,姚新生.中药复方研究现状和思路[J].化学进展2001,13(6)：481-485.
[77]于成功,吴寒.质子泵抑制剂的临床应用与研究进展.中华消化内镜杂志.2007,24(2)：74-75.
[78]邹品文,赵春景.质子泵抑制剂研究进展和研究方向.药学专论[J].2008,2：23-24.
[79]杨辉.铝碳酸镁和奥美拉唑联合用药治疗活动期胃溃疡40例.中国新药与临床杂志.2006,25(10)：770-772.
[80]李健,唐芙爱.胃黏膜保护剂的临床应用评价[J].中国医院用药评价与分析2003,3(3：133-137).
[81]张林,刘文忠.铋剂在根除幽门螺杆菌治疗中的作用[M].幽门螺杆菌研究进展.上海科学技术文献出版社.
[82]吴超斌,钟菊英.硫糖铝致麻疹样皮疹[J].药物不良反应杂志.2002,3：202.
[83]林鸿,俞淑静,穆晓燕.思密达的药理与临床应用[J].中国航空工业医药,2001,1(3)：75.
[84]陈建民,任建林.胃黏膜保护剂临床应用进展[J].world chin J Digestol 2005 NoVember;13(21): 2620-2622.
[85]郭荣臻,张宗海.不同抗酸制剂合用抗生素治疗胃溃疡及消除Hp疗效观察[J].河北医学.2002,8(6)：527-528.
[86]黄小梅.奥美拉唑和阿莫西林、甲硝唑联合治疗胃溃疡合并出血疗效观察[J].中原医刊.2004.31(19)：43-44.
[87]傅继华,温涛,徐琛,等.芦荟多糖对动物实验性胃溃疡的影响[J].中草药.2006,37(6)：895-897.
[88]顾洪丽.柴胡舒肝散治疗慢性萎缩性胃炎的临床体会[J].中医药导报.2008,4(7)：67.
[89]马洁.膈下逐瘀汤化裁治疗慢性萎缩性胃炎68例[J].江苏中医药.2005,26(4)：18.
[90]王新美,李晓琴.丹栀逍遥散临床应用举隅[J].河北中医药学报.2004,19(4)：14-15.
[91]白雪峰,刘梅君等.黄芪建中汤治疗消化性溃疡机理应用分析[J].光明中医,2008,9(9)：1351.
[92]张仲一,高岚,等.当归建中汤抗胃溃疡的实验研究[C].中国·天津第四届国际中医学药学术交流会议：226-267
[93]薛蓉.疏肝健脾养胃汤治疗消化性溃疡36例[J].中西医结合和祖国医学,2008,12(10)：920-921.
[94]唐保东.胃黏膜保护剂在胃溃疡治疗中的研究进展[M].中国处方药2006.5.NO.50.